Genetically modified PC12 brain grafts

Survivability and inducible nerve growth factor expression

D. C. Rohrer, G. Nilaver, V. Nipper, Curtis Machida

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Neural transplantation of genetically modified cells has been successfully employed to reverse functional deficits in animal models of neurodegenerative disorders, including Parkinson's disease. While implanted PC12 cells secrete dopamine in vivo and can ameliorate dopamine deficiency in parkinsonian rat model systems, these cells either degenerate within 2-3 wk postimplantation (presumably due to the lack of neural trophic factor support at the site of implantation), or in some cases, form a tumor mass leading to the death of the host animal. To address these limitations, we have developed a genetically modified PC12 cell line that can synthesize nerve growth factor (NGF) under the control of a zinc-inducible metallothionein promoter. When implanted in the rat striatum and under in vivo zinc stimulation, these cells will neurodifferentiate, express tyrosine hydroxylase, and will undergo survival through potential autocrine trophic support. This regulatable cell line and general approach may provide additional insight on the potential utilization of cell transplants for treatment of Parkinson's disease and other neurodegenerative disorders.

Original languageEnglish (US)
Pages (from-to)57-68
Number of pages12
JournalCell Transplantation
Volume5
Issue number1
DOIs
StatePublished - 1996

Fingerprint

Nerve Growth Factor
Grafts
Rats
Brain
Animals
Zinc
PC12 Cells
Cells
Transplants
Neurodegenerative Diseases
Parkinson Disease
Dopamine
Tumors
Cell Line
Tyrosine 3-Monooxygenase
Animal Models
Transplantation
Intercellular Signaling Peptides and Proteins
Neoplasms
Metallothionein

Keywords

  • Brain grafts
  • Nerve growth factor
  • Neural transplantation
  • Parkinson's disease

ASJC Scopus subject areas

  • Cell Biology
  • Transplantation

Cite this

Genetically modified PC12 brain grafts : Survivability and inducible nerve growth factor expression. / Rohrer, D. C.; Nilaver, G.; Nipper, V.; Machida, Curtis.

In: Cell Transplantation, Vol. 5, No. 1, 1996, p. 57-68.

Research output: Contribution to journalArticle

@article{d3a9e648137e4eb79cdf38f372ca228b,
title = "Genetically modified PC12 brain grafts: Survivability and inducible nerve growth factor expression",
abstract = "Neural transplantation of genetically modified cells has been successfully employed to reverse functional deficits in animal models of neurodegenerative disorders, including Parkinson's disease. While implanted PC12 cells secrete dopamine in vivo and can ameliorate dopamine deficiency in parkinsonian rat model systems, these cells either degenerate within 2-3 wk postimplantation (presumably due to the lack of neural trophic factor support at the site of implantation), or in some cases, form a tumor mass leading to the death of the host animal. To address these limitations, we have developed a genetically modified PC12 cell line that can synthesize nerve growth factor (NGF) under the control of a zinc-inducible metallothionein promoter. When implanted in the rat striatum and under in vivo zinc stimulation, these cells will neurodifferentiate, express tyrosine hydroxylase, and will undergo survival through potential autocrine trophic support. This regulatable cell line and general approach may provide additional insight on the potential utilization of cell transplants for treatment of Parkinson's disease and other neurodegenerative disorders.",
keywords = "Brain grafts, Nerve growth factor, Neural transplantation, Parkinson's disease",
author = "Rohrer, {D. C.} and G. Nilaver and V. Nipper and Curtis Machida",
year = "1996",
doi = "10.1016/0963-6897(95)02023-3",
language = "English (US)",
volume = "5",
pages = "57--68",
journal = "Cell Transplantation",
issn = "0963-6897",
publisher = "Cognizant Communication Corporation",
number = "1",

}

TY - JOUR

T1 - Genetically modified PC12 brain grafts

T2 - Survivability and inducible nerve growth factor expression

AU - Rohrer, D. C.

AU - Nilaver, G.

AU - Nipper, V.

AU - Machida, Curtis

PY - 1996

Y1 - 1996

N2 - Neural transplantation of genetically modified cells has been successfully employed to reverse functional deficits in animal models of neurodegenerative disorders, including Parkinson's disease. While implanted PC12 cells secrete dopamine in vivo and can ameliorate dopamine deficiency in parkinsonian rat model systems, these cells either degenerate within 2-3 wk postimplantation (presumably due to the lack of neural trophic factor support at the site of implantation), or in some cases, form a tumor mass leading to the death of the host animal. To address these limitations, we have developed a genetically modified PC12 cell line that can synthesize nerve growth factor (NGF) under the control of a zinc-inducible metallothionein promoter. When implanted in the rat striatum and under in vivo zinc stimulation, these cells will neurodifferentiate, express tyrosine hydroxylase, and will undergo survival through potential autocrine trophic support. This regulatable cell line and general approach may provide additional insight on the potential utilization of cell transplants for treatment of Parkinson's disease and other neurodegenerative disorders.

AB - Neural transplantation of genetically modified cells has been successfully employed to reverse functional deficits in animal models of neurodegenerative disorders, including Parkinson's disease. While implanted PC12 cells secrete dopamine in vivo and can ameliorate dopamine deficiency in parkinsonian rat model systems, these cells either degenerate within 2-3 wk postimplantation (presumably due to the lack of neural trophic factor support at the site of implantation), or in some cases, form a tumor mass leading to the death of the host animal. To address these limitations, we have developed a genetically modified PC12 cell line that can synthesize nerve growth factor (NGF) under the control of a zinc-inducible metallothionein promoter. When implanted in the rat striatum and under in vivo zinc stimulation, these cells will neurodifferentiate, express tyrosine hydroxylase, and will undergo survival through potential autocrine trophic support. This regulatable cell line and general approach may provide additional insight on the potential utilization of cell transplants for treatment of Parkinson's disease and other neurodegenerative disorders.

KW - Brain grafts

KW - Nerve growth factor

KW - Neural transplantation

KW - Parkinson's disease

UR - http://www.scopus.com/inward/record.url?scp=0029868390&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029868390&partnerID=8YFLogxK

U2 - 10.1016/0963-6897(95)02023-3

DO - 10.1016/0963-6897(95)02023-3

M3 - Article

VL - 5

SP - 57

EP - 68

JO - Cell Transplantation

JF - Cell Transplantation

SN - 0963-6897

IS - 1

ER -